Preclinical data show that Pulmatrix's inhaled antifungal drug can achieve high concentrations in the lungs, with low levels in the bloodstream
LEXINGTON, Mass., Oct. 31, 2017 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it will present preclinical data on its innovative inhaled antifungal drug, Pulmazole (formerly PUR1900), during the North American Cystic Fibrosis Conference to be held in Indianapolis, IN, from November 2-4, 2017.
PUR1900/Pulmazole combines an anti-fungal drug, itraconazole, with Pulmatrix's dry powder technology, called iSPERSE™. The technology allows drugs to be delivered to the lungs with much higher efficiency than other approaches can.
The data that Pulmatrix will present at the conference confirm that Pulmazole can achieve high concentrations of itraconazole in the lungs, where the drug needed to fight lung infections, while keeping levels of the drug in the bloodstream low.
"These data show that Pulmazole has the potential to be a major medical improvement over the current treatment, in which itraconazole is given as an oral pill," explained Robert W. Clarke, Ph.D., Chief Executive Officer of Pulmatrix. "The low concentrations in the bloodstream are expected to significantly reduce the often-dangerous side effects experienced with oral dosing, while the high levels in the lungs should bring a major increase in efficacy."
Pulmatrix is initially developing Pulmazole to treat a serious condition called allergic bronchopulmonary aspergillosis (ABPA), which is caused by pulmonary Aspergillus infections, suffered by asthma, cystic fibrosis patients and others with compromised lung function. The drug candidate has already received orphan drug status and two "Qualified Infectious Disease Product" (QIDP) designations from the U.S. Food & Drug Administration. It also has received an award from Cystic Fibrosis Foundation Therapeutics, the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to support its development.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole (PUR1900), an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and COPD. In addition, Pulmatrix has partnered with Vectura Group plc to develop Pulmatrix's drug candidate, PUR0200, for COPD for the U.S. market. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 10, 2017, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Pulmatrix, Inc.